Good morning, folks, and how are you today? Tired from watching yet another presidential debate? Well, attacking your to-do list will help you get focused. So, as we hustle our short people off to the schoolhouses, here are a few items to get you started. As always, please keep us in mind if you hear anything interesting, and tune in to our webinar tomorrow about ePedigree regulations (
see here). Have a great day...FDA OKs Eisai Drug For Epileptic Seizures (Reuters)
China To Crack Down On Procurement Corruption (China Daily)
Documents Show Problems At New England Compounder (Associated Press)
Watson Allowed To Sell Generic Actos Now, Judge Rules (Bloomberg News)
Statins May Lower Esophageal Cancer Risk (MedPage Today)
Lilly Diabetes Med Tops Others In Late-Stage Trial (Reuters)
Roche Cuts 100 Jobs In Diabetes Reorg (Indianapolis Business Journal)
EMA Wants To Revise Bovine Serum Test Requirements (InPharma Technologist)
Watson Sells Stake In Latin American Drugmaker (CNBC)
Glaxo Fund Seeks Early-Stage Alzheimer Detectors (Bloomberg News)
EDITOR'S NOTE: Please check this post for updates